Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.79 |
| ▸ | DRD2 | P14416 | 15/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911836 | 1.00 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL378782 | 1.00 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL12313324 | 1.00 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL4432044 | 0.99 | DRD3 (0.78) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL12313320 | 0.93 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL378413 | 0.93 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL11911833 | 0.93 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL4553423 | 0.93 | DRD3 (0.79) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL11915457 | 0.92 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL12313318 | 0.92 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| US-7855298-B2 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | DRD3 1131/4885KCNH2 4867/4885DRD2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.